Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BoneGen-TR is a medical-grade, resorbable calcium sulfate-based bone graft substitute primarily utilized in periodontal and oral surgery for the treatment of infrabony defects and ridge augmentation. It functions as an osteoconductive scaffold, providing a temporary physical matrix that facilitates the migration and attachment of osteogenic cells. A key feature of BoneGen-TR is its ability to act as a barrier in guided tissue regeneration (GTR) procedures; when applied over a defect, it prevents the rapid downgrowth of epithelial and connective tissues, thereby allowing slower-growing bone cells to populate the area. The material is typically supplied as a powder that, when mixed with a sterile aqueous solution, forms a moldable paste that hardens in situ. As the calcium sulfate resorbs over several weeks, it releases calcium ions into the local environment, supporting the mineralization of new bone tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BoneGen-TR.